Treatment of glaucoma in young nanophthalmic patients.
OBJECTIVE
To evaluate the criteria of diagnosis and management of secondary glaucoma in young nanophthalmic patients.


METHODS
Considering the anatomic features and clinical characteristics, 22 eyes of 11 patients were identified as bilateral nanophthalmos. Intraocular pressures (IOP) were checked with Goldmann applanation or Keeler pulse-air 2000 tonometer, and Nd-Yag laser was used for iridotomies. Prophylactic V-shaped unsutured sclerectomies over the pars plana were combined with trabeculectomy, and Mitomycin C (MMC) in 0.2 mg/ml concentration was applied.


RESULTS
Among 22 eyes of bilateral nanophthalmic patients 8 eyes had secondary angle-closure glaucoma. Laser iridotomies were performed in 6 eyes. Laser iridotomy and supplemental medical therapy were sufficient in 4 out of 6 eyes. Mean IOP dropped from 26.4 to 14.5 mmHg in these patients. Due to continuous increase of IOP in the other patients, they underwent trabeculectomy with V-shaped sclerostomy and intraoperative MMC application. Mean IOP dropped from 39.3 mmHg to 19.3 mmHg. Postoperative uveal effusion on other major complications were not observed. Mean age of these patients was 14.6 years during treatment.


CONCLUSIONS
Management of glaucoma in nanophthalmus is complicated. Initial treatment is medical. If it is insufficient, laser iridotomies and V-shaped sclerostomies with filtration surgery can be performed at any age.
Kocak
I
I
Glaucoma Section, Ankara Hospital, Department of Ophthalmology, Turkey.
Altintas
A G
AG
Yalvac
I S
IS
Nurozler
A
A
Kasim
R
R
Duman
S
S
D000293:Adolescent; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D007498:Iris / Q000601:surgery; D053685:Laser Therapy; D008297:Male; D008850:Microphthalmos / Q000150:complications* / Q000503:physiopathology; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use; D009883:Ophthalmic Solutions; D012599:Sclerostomy; D014130:Trabeculectomy; D016896:Treatment Outcome; D014792:Visual Acuity; D014794:Visual Fields
D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin